• Camostat Mesilate: Applied Research Workflows

  2026-09-24

  Use Camostat Mesilate to probe protease-dependent ENaC regulation and plasmin–TGF-β signaling, with workflows tailored to epithelial and hepatic models. A separate structure-guided antiviral study offers a useful assay-design comparison—not evidence that Camostat blocks the SARS-CoV-2 Spike–ACE2 interaction.

• Anagliptin Vasorelaxation: Kv Channels and SERCA

  2026-09-23

  A 2025 Acta Diabetologica study identified a vascular action of Anagliptin in phenylephrine-contracted rabbit aortic rings that involved voltage-dependent potassium channels and the SERCA pump. The findings provide a pharmacological framework for vasorelaxant mechanism research while indicating that the response was independent of endothelium, cAMP/PKA, and cGMP/PKG signaling in this ex vivo model.

• Dorsomorphin 2HCl: AMPK Workflow Guide

  2026-09-22

  Dorsomorphin 2HCl provides a practical pharmacological challenge for testing whether AMPK activation is causally responsible for metabolic phenotypes. This guide translates a probiotic–alcoholic steatosis study into reproducible formulation, control, readout, and troubleshooting decisions while accounting for the compound’s additional BMP activity.

• Polyethylenimine Linear for Mechanistic Assays

  2026-09-22

  Polyethylenimine Linear (PEI), MW 40,000 supports serum-compatible DNA delivery for transient gene expression, pathway rescue, and recombinant protein production. This guide translates the reagent into a reproducible workflow for mechanistic toxicology assays, including studies of arsenic-associated blood-testis barrier disruption.

• Cathepsin B inhibitor CA-074 Workflow Guide

  2026-09-21

  CA-074 provides a high-affinity, selective tool for testing cathepsin B involvement in proteolysis, cancer metastasis, neurotoxicity, and immune response modulation. It is suitable for controlled biochemical and cell-based experiments, but should not be treated as a broad protease inhibitor or as evidence of clinical efficacy without model-specific validation.

• SAR131675: Selective VEGFR-3 Inhibitor

  2026-09-21

  SAR131675 is a selective, ATP-competitive VEGFR-3 inhibitor for mechanistic studies of lymphangiogenesis, endothelial migration, fibrosis, and tumor biology. Its preclinical profile combines nanomolar VEGFR-3 activity with limited activity against VEGFR-1, VEGFR-2, and broad off-target panels, but development was discontinued because of adverse metabolic effects.

• Conformation-Guided uPAR-uPA Inhibitor Discovery

  2026-09-20

  Khanna and colleagues used molecular-dynamics-derived conformations of uPAR to discover IPR-456, a small molecule that disrupts the difficult uPAR·uPA protein-protein interaction. Biochemical, computational, and breast-cancer cell assays linked receptor binding with reduced uPA engagement and invasion, while the distinct effects on migration and adhesion clarified the selectivity of the mechanism.

• Fungal IAA Drives Ferroptosis in Rice Blast Conidia

  2026-09-19

  A 2026 Molecular Plant Pathology study shows that Magnaporthe oryzae-derived indole-3-acetic acid promotes iron accumulation, lipid peroxidation, and ferroptotic death during conidial development. Mutant analysis and phosphatidylethanolamine rescue experiments connect IAA-dependent lipid metabolism and autophagy with appressorium formation and rice blast pathogenicity.

• BMX-IN-1: A Host-Directed Infection Tool

  2026-09-18

  BMX-IN-1 is a selective BMX kinase inhibitor that connects cancer signaling with host-directed tuberculosis research. This article explains how BMX-dependent ATP6V1E1 phosphorylation can be translated into rigorous target-engagement, lysosomal-function, and macrophage infection assays.

• A-1331852: BCL-XL Inhibitor in Senescence

  2026-09-18

  A-1331852 is a selective BCL-XL inhibitor for dissecting apoptosis in chemotherapy-induced senescent cancer cells. This article connects BCL-XL–BIM complex disruption with assay design, dependency controls, and the translational limits of applying BH3-mimetic evidence across tumor models.

• Mestranol and Reversible Lysosomal Stress

  2026-09-17

  A 2026 Aquatic Toxicology study identifies mestranol as a pharmacological trigger of a reversible lysosomal storage–like state in zebrafish microglia. The work separates preserved phagocytic uptake from defective intracellular digestion and establishes a live model for investigating environmental neuroimmunotoxicity and microglial lysosomal vulnerability.

• Dual Enzyme-Responsive Peptides for Cancer Selectivity

  2026-09-17

  The reference study develops a zwitterionic peptide amphiphile that combines MMP-7-triggered disassembly with cathepsin B-directed intralysosomal assembly. This sequential mechanism produced a reported cancer selectivity index of 64.1 and tumor regression in an HT-29 xenograft model, while also highlighting important limits on translation beyond the tested enzyme and tumor context.

• H3K18 Lactylation Drives Astrocyte Pyroptosis

  2026-09-16

  Li et al. identify an H3K18 lactylation–NOD2 pathway that links glycolytic metabolism to bilirubin-induced astrocyte pyroptosis and neuroinflammation. By integrating primary astrocyte experiments, a bilirubin encephalopathy rat model, CUT&Tag, and RNA-seq, the study provides a mechanistic framework for investigating metabolic-epigenetic regulation in neonatal bilirubin injury.

• Mtb–BMX Signaling Blocks Lysosomal Acidification

  2026-09-16

  This study identifies an Mtb–Chp2–BMX signaling axis that phosphorylates host ATP6V1E1, disrupts V-ATPase assembly, and limits lysosomal acidification. The findings connect a secreted mycobacterial protein to a host kinase and suggest BMX-dependent lysosomal control as a possible host-directed strategy against intracellular tuberculosis.

• (R)-MG132: Proteasome Control in Cancer Assays

  2026-09-15

  Use (R)-MG132 as a stereochemically matched negative control when testing whether proteasome perturbation contributes to cancer-cell phenotypes. Its value is greatest in layered workflows that connect proteasome inhibition validation with HNRNPU–PHGDH metabolism studies.

8173 records 1/545 page Next 12345 下5页 Last page